A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
收藏DataCite Commons2026-03-23 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007117/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in
ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to
ALK inhibitors, as evidenced by progression-free survival (PFS).
提供机构：
Vivli
创建时间：
2021-05-06
